View Document Preview and Link Document Date: 2008-06-03 09:27:22 Open Document File Size: 11,74 KB Share Result on Facebook
City Gainesville / CRANBURY / / Company Amicus Therapeutics / Shire Human Genetic Therapies / PRNewswire-FirstCall / Shire plc / / Continent North America / Europe / / Country United States / / Event Business Partnership / FDA Phase / / Facility University of Florida / / IndustryTerm treatment of Fabry disease / treatment of human genetic diseases / biopharmaceutical company developing novel / treatment of Gaucher disease / treatment of Pompe disease / biopharmaceutical company developing small molecule / treatment of a range of human genetic diseases / chaperone technology / / MedicalCondition severe / chronic genetic diseases / musculoskeletal and pulmonary symptoms / disease / lysosomal storage disorders / Pompe Disease Pompe disease / Gaucher disease / Fabry disease / human genetic diseases / Pompe Disease CRANBURY / respiratory insufficiency / deficiency / cardio-respiratory failure / pulmonary and skeletal muscle function / Pompe disease / / Organization U.S. Food and Drug Administration's office of Orphan Products Development / University of Florida / / Person Barry J. Byrne / / Position investigator / Governor / professor of pediatrics / / Product AT2220 / Amigal(TM) / Plicera(TM) / / ProvinceOrState New Jersey / Florida / / Technology alpha / Pharmacological chaperone technology / / SocialTag 
Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease CRANBURY, N.J., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company